Literature DB >> 25522698

Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD.

Oren S Cohen1, Joab Chapman, Amos D Korczyn, Zeev Nitsan, Shmuel Appel, Chen Hoffmann, Hanna Rosenmann, Esther Kahana, Hedok Lee.   

Abstract

Familial Creutzfeldt-Jakob disease (fCJD) in Jews of Libyan ancestry is caused by an E200K mutation in the PRNP gene. While carriers are born with this mutation, they usually remain asymptomatic until middle age. Early detection of conversion is crucial for understanding and eventually for the treatment of the disease. The aim of this study was to report longitudinal MRI data in E200K individuals who eventually converted from healthy mutation carriers to clinically symptomatic CJD. As a part of a prospective study, asymptomatic E200K mutation carriers were scanned annually until their conversion to symptomatic disease. Standardized diffusion and anatomical MR sequences were performed before and after clinical conversion in the subjects and those were compared to 15 non-carrier siblings ("healthy controls"). Blinded radiological readings and region of interest analyses were performed. Radiological readings of individual cases failed to detect characteristic changes in the scans taken before the conversion. Region of interest analysis of diffusion changes in pre-symptomatic stage was inconclusive; however, ADC reduction was found in early and late stages of the disease. Computerized volumetric analysis revealed monotonic volume reductions in thalamus, putamen and caudate following conversion, and the lateral ventricles showed dilatation of up to 62 % after clinical conversion. Although the clinical manifestations at disease onset are variable, the diffusion abnormalities and/or volume changes in the thalamus and basal ganglia during conversion may indicate early involvement of the thalamostriatal neuronal circuit.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25522698     DOI: 10.1007/s00415-014-7615-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

Review 1.  Prion diseases.

Authors:  R S G Knight; R G Will
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

2.  The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation.

Authors:  J Chapman; J Ben-Israel; Y Goldhammer; A D Korczyn
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

3.  Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease.

Authors:  K Hsiao; Z Meiner; E Kahana; C Cass; I Kahana; D Avrahami; G Scarlato; O Abramsky; S B Prusiner; R Gabizon
Journal:  N Engl J Med       Date:  1991-04-18       Impact factor: 91.245

4.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

5.  The imaging appearance of Creutzfeldt-Jakob disease caused by the E200K mutation.

Authors:  Robert K Fulbright; Peter B Kingsley; Xiaodong Guo; Chen Hoffmann; Esther Kahana; Joab C Chapman; Isak Prohovnik
Journal:  Magn Reson Imaging       Date:  2006-09-07       Impact factor: 2.546

6.  Clinical heterogeneity and unusual presentations of Creutzfeldt-Jakob disease in Jewish patients with the PRNP codon 200 mutation.

Authors:  J Chapman; P Brown; L G Goldfarb; A Arlazoroff; D C Gajdusek; A D Korczyn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-10       Impact factor: 10.154

7.  Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.

Authors:  P Lyden; T Brott; B Tilley; K M Welch; E J Mascha; S Levine; E C Haley; J Grotta; J Marler
Journal:  Stroke       Date:  1994-11       Impact factor: 7.914

8.  Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study.

Authors:  Henriette J Tschampa; Petra Mürtz; Sebastian Flacke; Sebastian Paus; Hans H Schild; Horst Urbach
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

9.  Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers.

Authors:  Hedok Lee; Hanna Rosenmann; Joab Chapman; Peter B Kingsley; Chen Hoffmann; Oren S Cohen; Esther Kahana; Amos D Korczyn; Isak Prohovnik
Journal:  Brain       Date:  2009-03-24       Impact factor: 13.501

10.  Application of quantitative DTI metrics in sporadic CJD.

Authors:  E Caverzasi; R G Henry; P Vitali; I V Lobach; J Kornak; S Bastianello; S J Dearmond; B L Miller; H J Rosen; M L Mandelli; M D Geschwind
Journal:  Neuroimage Clin       Date:  2014-01-31       Impact factor: 4.881

View more
  4 in total

1.  Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease.

Authors:  Sonia M Vallabh; Eric Vallabh Minikel; Victoria J Williams; Becky C Carlyle; Alison J McManus; Chase D Wennick; Anna Bolling; Bianca A Trombetta; David Urick; Chloe K Nobuhara; Jessica Gerber; Holly Duddy; Ingolf Lachmann; Christiane Stehmann; Steven J Collins; Kaj Blennow; Henrik Zetterberg; Steven E Arnold
Journal:  BMC Med       Date:  2020-06-18       Impact factor: 8.775

2.  The genetic Creutzfeldt-Jakob disease with E200K mutation: analysis of clinical, genetic and laboratory features of 30 Chinese patients.

Authors:  Li-Ping Gao; Qi Shi; Kang Xiao; Jing Wang; Wei Zhou; Cao Chen; Xiao-Ping Dong
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

3.  The insomnia phenotype in genetic Creutzfeldt-Jakob disease based on the E200K mutation.

Authors:  Eva Feketeova; Dominika Jarcuskova; Alzbeta Janakova; Marianna Vitkova; Jozef Dragasek; Zuzana Gdovinova
Journal:  Prion       Date:  2019-01       Impact factor: 3.931

4.  Neuronal excitatory-to-inhibitory balance is altered in cerebral organoid models of genetic neurological diseases.

Authors:  Simote T Foliaki; Benjamin Schwarz; Bradley R Groveman; Ryan O Walters; Natalia C Ferreira; Christina D Orrù; Anna Smith; Aleksandar Wood; Olivia M Schmit; Phoebe Freitag; Jue Yuan; Wenquan Zou; Catharine M Bosio; James A Carroll; Cathryn L Haigh
Journal:  Mol Brain       Date:  2021-10-11       Impact factor: 4.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.